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Regional distribution of body fat in relation to DNA
methylation within the LPL, ADIPOQ and PPARγ promoters
in subcutaneous adipose tissue
D Drogan1,2, H Boeing1, J Janke3, B Schmitt4, Y Zhou1,5, J Walter4, T Pischon1,3 and S Tierling4
Obesity may be related to differential DNA methylation and thus to differential expression of key genes in adipose tissue
metabolism, such as LPL, ADIPOQ and PPARγ. Using subcutaneous adipose tissue (SAT) from 59 individuals of the European
Prospective Investigation into Cancer and Nutrition–Potsdam study, we performed quantitative DNA methylation analysis within
the promoters of LPL (LPL-CG1 and -CG2), ADIPOQ (ADIPOQ-CG1 and-CG2) and PPARγ (PPARγ-CG1). We then studied DNA
methylation in relation to SAT gene expression, body composition measured using whole-body magnetic resonance imaging, body
mass index (BMI), waist circumference (WC) and long-term changes in BMI and WC. For LPL-CG1 and LPL-CG2, higher methylation
levels were associated with lower LPL expression, but with higher past WC gain. LPL-CG1 was also positively associated with BMI,
WC, and visceral and subcutaneous fat mass. ADIPOQ-CG1 or -CG2 methylation exhibited no association with ADIPOQ expression or
with anthropometric parameters. PPARγ-CG1 methylation was significantly higher in individuals with higher visceral fat mass.
Among the investigated sites, LPL-CG1 methylation showed the strongest association with gene expression and regional body fat
distribution, thereby possibly linking the degree of obesity with major metabolic processes in SAT.
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INTRODUCTION
The contribution of epigenetic alterations such as DNA methyla-
tion to obesity or obesity-related comorbidities is not completely
understood; however, previous studies have linked measures of
obesity to differential DNA methylation in blood cells.1,2 Compar-
able investigations for adipose tissue (AT) are scarce, although AT
is the major fat-storage site and releases bioactive compounds
that modulate insulin sensitivity and systemic metabolism.3
Using human subcutaneous AT (SAT) samples we measured
DNA methylation at five CpG positions located within the
promoter regions of three genes with perceived impact on
metabolic health: (i) LPL—encoding lipoprotein lipase that
hydrolyses circulating triglyceride-rich lipoproteins and subse-
quent fatty acid uptake into AT,4 (ii) ADIPOQ—encoding the
insulin-sensitizing hormone adiponectin5 and (iii) PPARγ—encoding
the peroxisome proliferator-activated receptor γ, a transcription
factor regulating intermediary metabolism and insulin sensitivity.6,7
These data were used to investigate DNA-methylation levels in
relation to SAT expression of these genes, and to body weight,
weight gain and body fat distribution.
MATERIALS AND METHODS
In 2009, a random sample of the European Prospective Investiga-
tion (EPIC)–Potsdam cohort was invited for assessing body
composition and physical activity. Altogether, 816 participants
attended this re-examination and fulfilled the inclusion criteria
of having no severe disease within 1 year and no surgery
within 3 months before the examination. The study was approved
by the Ethics Committee of the medical association of the
State of Brandenburg (Germany). All participants provided
written informed consent. Our study included 60 participants
chosen randomly among participants with available peripheral
venous blood and SAT samples (n= 200). For subsequent
statistical analyses, we excluded one participant with missing
methylation data.
SAT and visceral AT were measured using whole-body magnetic
resonance imaging.8 Trained personnel measured waist circum-
ference (WC), body weight and body mass index (BMI). Using past
anthropometric data of the EPIC–Potsdam baseline examination
(collected on average 14.5 years before our investigation),9 we
calculated 5-year changes in body weight, BMI and WC.
DNA and RNA were extracted from SAT samples using the
Qiagen AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany).
Extraction of DNA from blood was performed using the DNeasy
Blood & Tissue Kit. Quantity and integrity of purified DNA and RNA
was analysed using the NanoDrop Photometer (PeqLab, Erlangen,
Germany) and the Bioanalyser (Agilent Technologies, Böblingen,
Germany). Two micrograms of RNA were reverse-transcribed to
complementary DNA (cDNA) using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Darmstadt,
Germany).
Chromosomal DNA (500 ng) was treated with sodium bisulfite
using the EZ DNA Methylation kit (Zymo Research, Irvine, CA, USA)
according to the manufacturer’s protocol. Amplicons were
generated using bisulfite-specific primers (Supplementary Table
1). Amplicons were purified using 1 U of ExonucleaseI/Shrimp
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Alkaline Phosphatase mix at 37 °C for 30 min followed by 80 °C for
15min. Purified amplicons were subjected to single-nucleotide
primer extension with single nucleotide primer extension with ion-
pair reversed-phase high performance liquid chromatography
(SIRPH) analysis.10 Experimental conduction was carried out as
described previously11 (details are given in Supplementary Table 2).
SAT samples from three normal-weight and three obese participants
were used (i) for selecting potentially informative CpG positions in
the candidate genes using methylation data obtained from Illumina
450K BeadChip arrays and NGS-based bisulfite profiling focusing on
absence of sequence polymorphism, high variability of methylation
levels and association with BMI/gene expression (date not shown),
and (ii) for validating SIRPH-based DNA methylation results with Bi-
PROF.12 The correlation between both methods was 0.97 (P=0.005)
for LPL-CG2, 0.87 (P=0.024) for ADIPOQ-CG1 and 0.94 (P=0.005) for
PPARγ-CG1.
SAT gene expression of LPL, ADIPOQ and PPARγ was assessed
with real-time PCR using the Applied Biosystems 7500 Fast real-
time PCR system with TaqMan technology (ABI, Darmstadt,
Germany). The two-step PCR conditions were 20 s at 95 °C, 40
cycles with 3 s at 95 °C and 30 s at 60 °C (5 μl reaction volume, 4 ng
template). All samples and controls were run in triplicates. For
each amplification cycle, a threshold cycle (Ct) value was obtained,
and the ΔCt value was calculated as the Ct difference between
target gene and 18S rRNA. Fold upregulation of gene expression
compared with weakest expression was calculated using the
2−ΔΔCt method.13
Statistical analysis was performed using the SAS Enterprise
Guide, release 9.2 (SAS Institute, Cary, NC, USA). We calculated
means ± s.d. or frequencies of selected participants’ characteristics.
In linear regression models, we used anthropometric parameters
or gene expression as dependent variables, SAT methylation as
predictor and age and sex as covariates. The resulting β-
coefficients indicate the change in the respective dependent
variable associated with a 0.1 unit increase in DNA-methylation
levels.
RESULTS
This analysis included 18 men and 41 women aged 63.1 ± 8.7 years
(Table 1).
In SAT probes, LPL-CG1 methylation correlated strongly with
LPL-CG2 methylation (rs = 0.63, Po0.001). The correlation
between SAT- and blood methylation—available for LPL and
ADIPOQ—was very weak (Supplementary Table 3). LPL-CG1 and
LPL-CG2 methylation levels were inversely related to LPL gene
expression (Table 2). Each 0.1 unit increase in LPL-CG1 methylation
was associated with 3.7 kg m-2 higher BMI, 1.1 kg higher visceral
AT mass and past weight gain of 1.5 kg per 5 years. SAT-
methylation levels between ADIPOQ-CG1 and ADIPOQ-CG2
correlated weakly (rs = 0.29, P= 0.023), but exhibited no significant
association with ADIPOQ gene expression or anthropometric
parameters (Table 2). With increasing PPARγ-CG1 methylation we
observed significantly increased body fat and visceral AT mass.
Table 1. Characteristics of 59 randomly selected participants of a sub-
study of EPIC–Potsdam
Characteristics Value
Age, year, mean± s.d. 63.1± 8.7
Male sex, % 30.5
BMI, kgm− 2, mean± s.d. 28.6± 4.6
WC, cm, mean± s.d. 95.5± 11.6
SAT, kg, mean± s.d.a 20.4± 7.4
VAT, kg, mean± s.d.a 3.8± 1.6
VAT from fat, %, mean± s.d.a 16.3± 7.4
Total fat from body mass, %, mean± s.d.a 30.4± 7.1
ΔWeight, kg per 5 years, mean± s.d.b 2.1± 2.5
ΔBMI, kgm− 2 per 5 years, mean± s.d.b 0.8± 1.0
ΔWC, cm per 5 years, mean± s.d.b 3.9± 2.9
LPL-CG1 methylation, mean± s.d.c 0.38± 0.05
LPL-CG2 methylation, mean± s.d.c 0.25± 0.05
LPL gene expression, mean± s.d.d 3.09± 1.42
ADIPOQ-CG1 methylation, mean± s.d.c 0.82± 0.02
ADIPPOQ-CG2 methylation, mean± s.d.c 0.56± 0.14
ADIPOQ gene expression, mean± s.d.d 1.92± 0.80
PPARγ-CG1 methylation, mean± s.d.c 0.34± 0.08
PPARγ gene expression, mean± s.d.d 2.24± 0.88
Abbreviations: BMI, body mass index; Δ, change; SAT, subcutaneous
adipose tissue; VAT, visceral adipose tissue; WC, waist circumference. aData
derived from whole-body magnetic resonance imaging available for 49
participants. bAverage time between baseline examination (1994–1998)
and the current re-examination was 14.5 years. cMethylation β-value
measured in DNA from SAT. dSAT expression data, normalized to the
expression of 18S rRNA and relative to the weakest expression observed in
this study population.
Table 2. Association of LPL-, ADIPOQ- and PPARγ-promoter methylation in DNA from subcutaneous adipose tissue with anthropometric parameters
and gene expression
LPL-CG1 LPL-CG2 ADIPOQ-CG1 ADIPOQ-CG2 PPARγ-CG1
βa P-value βa P-value βa P-value βa P-value βa P-value
BMI (kgm− 2) 3.7 0.003 1.2 0.330 0.7 0.810 0.1 0.830 0.8 0.350
WC (cm) 9.9 0.001 3.95 0.191 6.0 0.392 1.7 0.131 2.9 0.135
SAT (kg)b 6.9 o0.001 2.3 0.347 1.2 0.807 0.7 0.338 2.3 0.091
VAT (kg)b 1.1 0.012 1.0 0.060 1.1 0.306 0.2 0.160 0.7 0.013
VAT from fat (%)b 0.5 0.730 2.9 0.086 3.9 0.249 0.3 0.544 1.6 0.095
Total fat from body mass (%)b 5.7 o0.001 3.4 0.081 0.7 0.859 0.9 0.164 2.3 0.038
ΔWeight (kg per 5 years)c 1.5 0.019 0.8 0.217 1.7 0.267 0.3 0.271 0.5 0.205
ΔBMI (kgm− 2 per 5 years)c 0.6 0.011 0.3 0.156 0.6 0.333 0.1 0.281 0.2 0.173
ΔWC (cm per 5 years)c 1.4 0.047 1.5 0.033 1.6 0.341 0.4 0.117 0.3 0.467
SAT gene expressiond − 1.0 0.009 − 0.7 0.047 0.1 0.870 o0.1 0.869 − 0.2 0.199
Abbreviations: BMI, body mass index; Δ, change; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; WC, waist circumference. aβ-coefficients from
the regression analyses are age- and sex-adjusted and represent the change in anthropometric parameters or gene expression (left column) for every 0.1 unit
increase in the SAT-methylation level. bData derived from whole-body magnetic resonance imaging available for 49 participants. cAverage time between
baseline examination (1994–1998) and the current re-examination was 14.5 years. dReferring to LPL gene expression for LPLCG1 and -CG2, to ADIPOQ gene
expression for ADIPOQ-CG1 and -CG2 and to PPARγ gene expression for PPARγ–CG1. Data were normalized to the expression of 18S rRNA and relative to the
weakest expression observed in this study population.
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DISCUSSION
As epigenetic alterations in AT may be associated with obesity-
related phenotypes, we performed quantitative analysis of single
CpG methylation within the LPL, ADIPOQ and PPARγ promoters.
Among the investigated sites, SAT-methylation levels in LPL-CG1
exhibited the strongest inverse association with gene expression
and the strongest positive association with measures of regional
body fat distribution.
According to the ‘AT expandability hypothesis’, individuals
possess a threshold for preferentially depositing fat in SAT during
periods of energy surplus.14 Once this threshold is exceeded,
fat is also stored in visceral AT, liver or muscles. Given the
gatekeeper function of LPL to direct fatty acid entry into AT,4 LPL
activity in AT might decrease as a result of chronic energy surplus
and limits in lipid-storage capacity. Indeed, we observed that
increased fat was associated with increased LPL promoter
methylation along with decreased LPL expression. Although
substantially weaker, similar observations were made for PPARγ,
a key regulator of AT metabolism,6,7 suggesting that the metabolic
capacity of SAT is linked with obesity-related epigenetic
mechanisms.15
Although adiponectin is mainly released by AT, adiponectin levels
are decreased in obesity.5 One may speculate that reduced
transcription due to methylation of ADIPOQ sites may contribute to
this paradox. Yet, ADIPOQ-methylation levels exhibited no association
with ADIPOQ gene expression or anthropometric parameters in our
study, but for future investigations, methylation sites with a stronger
association with gene expression are available.16
This investigation profits from the availability of human SAT
samples and in-depth anthropometric phenotyping of study
participants. To our knowledge, no previous human study targeted
body fat distribution as well as longitudinal changes in obesity
markers in relation to SAT methylation within the ADIPOQ, LPL or
PPARγ genes. In view of the limited statistical power, the significant
association of LPL-CG1 methylation with gene expression and
anthropometry is noteworthy. Although we selected three well-
established candidate genes of metabolic diseases with exclusive or
predominant expression in AT, the focus on only five CpG positions
is a limitation. To our knowledge, ADIPOQ–CG2 is the only site
with comparable data being reported by others—and its SAT-
methylation levels were inversely related to ADIPOQ expression in
females.17 As epigenetic marks display cell specificity, any associa-
tion between DNA methylation and anthropometric markers might
have been influenced by changes in cell composition, for example,
obesity-induced macrophage infiltration. Although most CpGs of the
human genome demonstrate comparable DNA methylation pattern
across cell types, homogeneous cell samples are preferable for
epigenetic studies.18 Furthermore, our data are correlative and we
cannot prove the temporal relationship between the investigated
variables. Specifically, obesity may be a consequence of DNA
methylation established in early development,19 but weight change
may as well alter DNA methylation during adulthood.20 In either
case, the regional body fat distribution appears to be associated
with differential DNA methylation in genes encoding for key
proteins in AT metabolism, thereby possibly linking the degree of
obesity with the susceptibility to develop metabolic dysfunction.
However, we observed a relation between the methylation status
and expression only in one out of five sites.
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